Healthcare breakthroughs are extending the lives of multiple sclerosis (MS) patients and cancer survivors, creating a growing cohort of individuals navigating a dual diagnosis. Determining the relationship between MS and cancer risk remains challenging, with inconclusive findings confounded by age, risk exposures, comorbidities, genetics and the ongoing introduction of new MS disease-modifying therapies (DMTs) across study periods.
This research places significant emphasis on cancer survival, with less attention given to the impact on MS outcomes. Our review explores the existing literature on MS, cancer risk and the intersection of DMTs and cancer treatments. We aim to navigate the complexities of managing MS in cancer survivors to optimise outcomes for both conditions. Continuous research and the formulation of treatment guidelines are essential for guiding future care. Collaboration between neuro-immunology and oncology is crucial, with a need to establish databases for retrospective and ultimately prospective analysis of outcomes in these rapidly evolving fields.
CapassoNVirgilioECovelliA, et al. Aging in multiple sclerosis: From childhood to old age, etiopathogenesis, and unmet needs: A narrative review. Front Neurol2023; 14: 1207617.
2.
AttfieldKEJensenLTKaufmannM, et al. The immunology of multiple sclerosis. Nat Rev Immunol2022; 22(12): 734–750.
3.
van WeverwijkAde VisserKE. Mechanisms driving the immunoregulatory function of cancer cells. Nat Rev Cancer2023; 23(4): 193–215.
4.
ValenciaJCEgbukichiNErwin-CohenRA. Autoimmunity and cancer, the paradox comorbidities challenging therapy in the context of preexisting autoimmunity. J Interferon Cytokine Res2019; 39(1): 72–84.
5.
SakowskaJArcimowiczŁJankowiakM, et al. Autoimmunity and cancer-two sides of the same coin. Front Immunol2022; 13: 793234.
6.
OcadlikovaDLeccisoMIsidoriA, et al. Chemotherapy-induced tumor cell death at the crossroads between immunogenicity and immunotolerance: Focus on acute myeloid leukemia. Front Oncol2019; 9: 1004.
7.
BridgeFBrothertonJStankovichJ, et al. Risk of cervical abnormalities for women with multiple sclerosis treated with moderate-efficacy and high-efficacy disease-modifying therapies. Neurology2024; 102(4): e208059.
8.
ElkoshiZ. Cancer and autoimmune diseases: A tale of two immunological opposites?Front Immunol2022; 13: 821598.
9.
MaW-TGaoFGuK, et al. The role of monocytes and macrophages in autoimmune diseases: A comprehensive review. Front Immunol2019; 10: 1140.
10.
VenkenKHellingsNThewissenM, et al. Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level. Immunology2008; 123(1): 79–89.
11.
TisonAGaraudSChicheL, et al. Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases. Nat Rev Rheumatol2022; 18(11): 641–656.
12.
MarrieRAFiskJDFitzgeraldK, et al. Etiology, effects and management of comorbidities in multiple sclerosis: Recent advances. Front Immunol2023; 14: 1197195.
13.
DurieuxNVandenputSPasleauF. [OCEBM levels of evidence system]. Rev Med Liege2013; 68(12): 644–649.
14.
LiuQKangJYinY, et al. Association between multiple sclerosis and cancer risk: An extensive review/meta and Mendelian randomization analyses. Mult Scler Relat Disord2023; 76: 104798.
15.
Bosco-LévyPFochCGrelaudA, et al. Incidence and risk of cancer among multiple sclerosis patients: A matched population-based cohort study. Eur J Neurol2022; 29(4): 1091–1099.
16.
KuiperJGOverbeekJAFochC, et al. Incidence of malignancies in patients with multiple sclerosis versus a healthy matched cohort: A population-based cohort study in the Netherlands using the PHARMO Database Network. J Clin Neurosci2022; 103: 49–55.
17.
MariottiniAForciBGualdaniE, et al. Incidence of malignant neoplasms and mortality in people affected by multiple sclerosis in the epoch of disease-modifying treatments: A population-based study on Tuscan residents. Mult Scler Relat Disord2022; 60: 103679.
18.
MaricGPekmezovicTMesarosS, et al. Occurrence of malignant diseases in patients with multiple sclerosis: Population-based MS Registry data. Neurol Sci2022; 43(12): 6839–6846.
19.
ZeccaCDisantoGSaccoR, et al. Increasing cancer risk over calendar year in people with multiple sclerosis: A case-control study. J Neurol2021; 268(3): 817–824.
20.
MarrieRAMaxwellCMaharA, et al. Cancer incidence and mortality rates in multiple sclerosis: A matched cohort study. Neurology2021; 96(4): e501–e512.
21.
GryttenNMyhrKMCeliusEG, et al. Incidence of cancer in multiple sclerosis before and after the treatment era- a registry- based cohort study. Mult Scler Relat Disord2021; 55: 103209.
22.
GhajarzadehMMohammadiASahraianMA. Risk of cancer in multiple sclerosis (MS): A systematic review and meta-analysis. Autoimmun Rev2020; 19(10): 102650.
23.
D’AmicoEChisariCGArenaS, et al. Cancer risk and multiple sclerosis: Evidence from a large Italian cohort. Front Neurol2019; 10: 337.
24.
GryttenNMyhrKMCeliusEG, et al. Risk of cancer among multiple sclerosis patients, siblings, and population controls: A prospective cohort study. Mult Scler2020; 26(12): 1569–1580.
25.
HongellKKurkiSSumelahtiML, et al. Risk of cancer among Finnish multiple sclerosis patients. Mult Scler Relat Disord2019; 35: 221–227.
26.
NørgaardMVeresKDiddenEM, et al. Multiple sclerosis and cancer incidence: A Danish nationwide cohort study. Mult Scler Relat Disord2019; 28: 81–85.
27.
EtemadifarMJahanbani-ArdakaniHGhaffariS, et al. Cancer risk among patients with multiple sclerosis: A cohort study in Isfahan, Iran. Caspian J Intern Med2017; 8(3): 172–177.
28.
GryttenNMyhrKMCeliusEG, et al. Cancer related mortality in multiple sclerosis. A population based cohort study. Mult Scler Relat Disord2023; 69: 104417.
29.
GaindhDKavakKSTeterB, et al. Decreased risk of cancer in multiple sclerosis patients and analysis of the effect of disease modifying therapies on cancer risk. J Neurol Sci2016; 370: 13–17.
30.
CapkunGDahlkeFLahozR, et al. Mortality and comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: An observational study using the US Department of Defense administrative claims database. Mult Scler Relat Disord2015; 4(6): 546–554.
31.
RoshanisefatHBahmanyarSHillertJ, et al. All-cause mortality following a cancer diagnosis amongst multiple sclerosis patients: A Swedish population-based cohort study. Eur J Neurol2015; 22(7): 1074–1080.
32.
SunLMLinCLChungCJ, et al. Increased breast cancer risk for patients with multiple sclerosis: A nationwide population-based cohort study. Eur J Neurol2014; 21(2): 238–244.
33.
KingwellEBajdikCPhillipsN, et al. Cancer risk in multiple sclerosis: Findings from British Columbia, Canada. Brain2012; 135(Pt. 10): 2973–2979.
34.
PalSKHurriaA. Impact of age, sex, and comorbidity on cancer therapy and disease progression. J Clin Oncol2010; 28(26): 4086–4093.
35.
FuZXuHYueL, et al. Immunosenescence and cancer: Opportunities and challenges. Medicine (Baltimore)2023; 102(47): e36045.
36.
BattramAMBachillerMMartín-AntonioB. Senescence in the development and response to cancer with immunotherapy: A double-edged sword. Int J Mol Sci2020; 21(12): 4346.
37.
Oscar OkwudiriOLoreDRoseN, et al. Chemotherapy-induced changes and immunosenescence of CD8+ T-cells in patients with breast cancer. Anticancer Res2015; 35(3): 1481–1489.
38.
CollonguesNDurand-DubiefFLebrun-FrenayC, et al. Cancer and multiple sclerosis: 2023 recommendations from the French Multiple Sclerosis Society. Mult Scler2024; 30: 899–924.
39.
FangTZhangZZhouH, et al. Multiple sclerosis and breast cancer risk: A meta-analysis of observational and Mendelian randomization studies. Front Neuroinform2023; 17: 1154916.
40.
MelamedELeeMW. Multiple sclerosis and cancer: The Ying-Yang effect of disease modifying therapies. Front Immunol2019; 10: 2954.
41.
RagonesePAridonPVazzolerG, et al. Association between multiple sclerosis, cancer risk, and immunosuppressant treatment: A cohort study. BMC Neurol2017; 17: 1–6.
42.
LebrunCVermerschPBrassatD, et al. Cancer and multiple sclerosis in the era of disease-modifying treatments. J Neurol2011; 258: 1304–1311.
43.
Ruetsch-ChelliCOkudaDTRocherF, et al. Sphingosine-1 phosphate receptor modulators increase in vitro melanoma cell line proliferation at therapeutic doses used in patients with multiple sclerosis. Neurol Ther2023; 12(1): 289–302.
44.
KelseyACasinelliGTandonM, et al. Breast carcinoma after ocrelizumab therapy in multiple sclerosis patients: A case series and literature review. J Cent Nerv Syst Dis2021; 13: 11795735211037785.
45.
BridgeFBrothertonJMLFoongY, et al. Risk of cervical pre-cancer and cancer in women with multiple sclerosis exposed to high efficacy disease modifying therapies. Front Neurol2023; 14: 1119660.
46.
NikfarSRahimiRAbdollahiM. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type. Clin Ther2010; 32(11): 1871–1888.
47.
NewsomeSDScottTFArnoldDL, et al. Long-term outcomes of peginterferon beta-1a in multiple sclerosis: Results from the ADVANCE extension study, ATTAIN. Ther Adv Neurol Disord2018; 11: 1756286418791143.
48.
CalabresiPAKieseierBCArnoldDL, et al. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): A randomised, phase 3, double-blind study. Lancet Neurol2014; 13(7): 657–665.
49.
Sandberg-WollheimMKornmannGBischofD, et al. The risk of malignancy is not increased in patients with multiple sclerosis treated with subcutaneous interferon beta-la: Analysis of data from clinical trial and post-marketing surveillance settings. Mult Scler2011; 17(4): 431–440.
50.
KingwellEEvansCZhuF, et al. Assessment of cancer risk with β-interferon treatment for multiple sclerosis. J Neurol Neurosurg Psychiatry2014; 85(10): 1096–1102.
51.
BloomgrenGSperlingBCushingK, et al. Assessment of malignancy risk in patients with multiple sclerosis treated with intramuscular interferon beta-1a: Retrospective evaluation using a health insurance claims database and postmarketing surveillance data. Ther Clin Risk Manag2012; 8: 313–321.
52.
ParkerBSRautelaJHertzogPJ. Antitumour actions of interferons: Implications for cancer therapy. Nat Rev Cancer2016; 16(3): 131–144.
53.
VitaleGde HerderWWvan KoetsveldPM, et al. IFN-beta is a highly potent inhibitor of gastroenteropancreatic neuroendocrine tumor cell growth in vitro. Cancer Res2006; 66(1): 554–562.
54.
VitaleGvan EijckCHvan Koetsveld IngPM, et al. Type I interferons in the treatment of pancreatic cancer: Mechanisms of action and role of related receptors. Ann Surg2007; 246(2): 259–268.
55.
SchiavoniGMatteiFGabrieleL. Type I interferons as stimulators of DC-mediated cross-priming: Impact on anti-tumor response. Front Immunol2013; 4: 483.
56.
FuertesMBKachaAKKlineJ, et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med2011; 208(10): 2005–2016.
57.
DedoniSOlianasMCOnaliP. Interferon-β induces apoptosis in human SH-SY5Y neuroblastoma cells through activation of JAK-STAT signaling and down-regulation of PI3K/Akt pathway. J Neurochem2010; 115(6): 1421–1433.
58.
Chawla-SarkarMLeamanDWBordenEC. Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: Correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin Cancer Res2001; 7(6): 1821–1831.
59.
YeZDongHLiY, et al. Prevalent homozygous deletions of type I interferon and defensin genes in human cancers associate with immunotherapy resistance. Clin Cancer Res2018; 24(14): 3299–3308.
60.
JohnsonKBrooksBCohenJ, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology1995; 45(7): 1268–1276.
61.
JohnsonKBrooksBCohenJ, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology1998; 50(3): 701–708.
62.
TselisAKhanOLisakRP. Glatiramer acetate in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat2007; 3(2): 259–267.
63.
DolladilleCChrétienBPeyro-Saint-PaulL, et al. Association between disease-modifying therapies prescribed to persons with multiple sclerosis and cancer: A WHO pharmacovigilance database analysis. Neurotherapeutics2021; 18(3): 1657–1664.
64.
LebrunCRocherF. Cancer risk in patients with multiple sclerosis: Potential impact of disease-modifying drugs. CNS Drugs2018; 32(10): 939–949.
65.
PolmanCHO’ConnorPWHavrdovaE, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med2006; 354(9): 899–910.
66.
SabolRANoxonVSartorO, et al. Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR). Cancer Med2017; 6(7): 1541–1551.
67.
AlpingPAsklingJBurmanJ, et al. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Ann Neurol2020; 87(5): 688–699.
68.
ButzkuevenHKapposLWiendlH, et al. Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). J Neurol Neurosurg Psychiatry2020; 91(6): 660–668.
69.
FoleyJCarrillo-InfanteCSmithJ, et al. The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis. Mult Scler Relat Disord2020; 39: 101863.
70.
GarofaloAChiriviRGFoglieniC, et al. Involvement of the very late antigen 4 integrin on melanoma in interleukin 1-augmented experimental metastases. Cancer Res1995; 55(2): 414–419.
71.
MoriYShimizuNDallasM, et al. Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood2004; 104(7): 2149–2154.
72.
QianFVauxDLWeissmanIL. Expression of the integrin alpha 4 beta 1 on melanoma cells can inhibit the invasive stage of metastasis formation. Cell1994; 77(3): 335–347.
73.
CalabresiPARadueEWGoodinD, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol2014; 13(6): 545–556.
74.
CohenJABarkhofFComiG, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med2010; 362(5): 402–415.
75.
ComiGO’ConnorPMontalbanX, et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler2010; 16(2): 197–207.
76.
LublinFMillerDHFreedmanMS, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): A phase 3, randomised, double-blind, placebo-controlled trial. Lancet2016; 387(10023): 1075–1084.
77.
KillesteinJLeursCEHoogervorstELJ, et al. Five cases of malignant melanoma during fingolimod treatment in Dutch patients with MS. Neurology2017; 89(9): 970–972.
78.
StamatellosVPSiafisSPapazisisG. Disease-modifying agents for multiple sclerosis and the risk for reporting cancer: A disproportionality analysis using the US Food and Drug Administration Adverse Event Reporting System database. Br J Clin Pharmacol2021; 87(12): 4769–4779.
79.
MahajanKRKoJSTetzlaffMT, et al. Merkel cell carcinoma with fingolimod treatment for multiple sclerosis: A case report. Mult Scler Relat Disord2017; 17: 12–14.
80.
PapathemeliDGräfeRHildebrandtU, et al. Development of a primary cutaneous CD30(+) anaplastic large-cell T-cell lymphoma during treatment of multiple sclerosis with fingolimod. Mult Scler2016; 22(14): 1888–1890.
81.
CohanSGodwinJGaedekeL. Acute lymphoblastic leukemia in a man treated with fingolimod for relapsing multiple sclerosis. J Investig Med High Impact Case Rep2015; 3(1): 2324709615575551.
82.
VermaRFosterREHorganK, et al. Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer. Breast Cancer Res2016; 18(1): 10.
83.
TriplettJKermodeAGCorbettA, et al. Warts and all: Fingolimod and unusual HPV-associated lesions. Mult Scler2019; 25(11): 1547–1550.
84.
MhannaENouchiALouapreC, et al. Human papillomavirus lesions in 16 MS patients treated with fingolimod: Outcomes and vaccination. Mult Scler2021; 27(11): 1794–1798.
85.
BenedettiMDMarangiABozzettiS, et al. HPV-related papillary squamous cell carcinoma of the tonsil during treatment with fingolimod. Mult Scler Relat Disord2018; 23: 24–26.
86.
CuvillierO. Downregulating sphingosine kinase-1 for cancer therapy. Expert Opin Ther Targets2008; 12(8): 1009–1020.
87.
WhiteCAlshakerHCooperC, et al. The emerging role of FTY720 (Fingolimod) in cancer treatment. Oncotarget2016; 7(17): 23106–23127.
88.
UbaiTAzumaHKotakeY, et al. FTY720 induced Bcl-associated and Fas-independent apoptosis in human renal cancer cells in vitro and significantly reduced in vivo tumor growth in mouse xenograft. Anticancer Res2007; 27(1a): 75–88.
89.
AzumaHTakaharaSHorieS, et al. Induction of apoptosis in human bladder cancer cells in vitro and in vivo caused by FTY720 treatment. J Urol2003; 169(6): 2372–2377.
90.
ZhangNQiYWadhamC, et al. FTY720 induces necrotic cell death and autophagy in ovarian cancer cells: A protective role of autophagy. Autophagy2010; 6(8): 1157–1167.
91.
SalinasNROshimaCTCuryPM, et al. FTY720 and lung tumor development. Int Immunopharmacol2009; 9(6): 689–693.
92.
NevianiPSanthanamROaksJJ, et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest2007; 117(9): 2408–2421.
93.
RobertsKGSmithAMMcDougallF, et al. Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers. Cancer Res2010; 70(13): 5438–5447.
94.
HoJWManKSunCK, et al. Effects of a novel immunomodulating agent, FTY720, on tumor growth and angiogenesis in hepatocellular carcinoma. Mol Cancer Ther2005; 4(9): 1430–1438.
95.
LucasdaSilvaLBRibeiroDACuryPM, et al. FTY720 treatment in experimentally urethane-induced lung tumors. J Exp Ther Oncol2008; 7(1): 9–15.
96.
LiuQZhaoXFrissoraF, et al. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood2008; 111(1): 275–284.
97.
TonelliFLimKGLoveridgeC, et al. FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells. Cell Signal2010; 22(10): 1536–1542.
98.
NagaokaYOtsukiKFujitaT, et al. Effects of phosphorylation of immunomodulatory agent FTY720 (fingolimod) on antiproliferative activity against breast and colon cancer cells. Biol Pharm Bull2008; 31(6): 1177–1181.
99.
LimKGTonelliFLiZ, et al. FTY720 analogues as sphingosine kinase 1 inhibitors: Enzyme inhibition kinetics, allosterism, proteasomal degradation, and actin rearrangement in MCF-7 breast cancer cells. J Biol Chem2011; 286(21): 18633–18640.
100.
ZhangLWangHZhuJ, et al. FTY720 reduces migration and invasion of human glioblastoma cell lines via inhibiting the PI3K/AKT/mTOR/p70S6K signaling pathway. Tumour Biol2014; 35(11): 10707–10714.
101.
Estrada-BernalAPalanichamyKRay ChaudhuryA, et al. Induction of brain tumor stem cell apoptosis by FTY720: A potential therapeutic agent for glioblastoma. Neuro Oncol2012; 14(4): 405–415.
102.
LeeTKManKHoJW, et al. FTY720: A promising agent for treatment of metastatic hepatocellular carcinoma. Clin Cancer Res2005; 11(23): 8458–8466.
103.
HungJHLuYSWangYC, et al. FTY720 induces apoptosis in hepatocellular carcinoma cells through activation of protein kinase C delta signaling. Cancer Res2008; 68(4): 1204–1212.
104.
FujinoMLiXKKitazawaY, et al. Distinct pathways of apoptosis triggered by FTY720, etoposide, and anti-Fas antibody in human T-lymphoma cell line (Jurkat cells). J Pharmacol Exp Ther2002; 300(3): 939–945.
105.
SzymiczekAPastorinoSLarsonD, et al. FTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse model. J Transl Med2017; 15(1): 58.
106.
ZhengTMengXWangJ, et al. PTEN- and p53-mediated apoptosis and cell cycle arrest by FTY720 in gastric cancer cells and nude mice. J Cell Biochem2010; 111(1): 218–228.
107.
RosaRMarcianoRMalapelleU, et al. Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models. Clin Cancer Res2013; 19(1): 138–147.
108.
CristóbalIMansoRRincónR, et al. PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential. Mol Cancer Ther2014; 13(4): 938–947.
109.
LaMontagneKLittlewood-EvansASchnellC, et al. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res2006; 66(1): 221–231.
110.
ChuaCWLeeDTLingMT, et al. FTY720, a fungus metabolite, inhibits in vivo growth of androgen-independent prostate cancer. Int J Cancer2005; 117(6): 1039–1048.
111.
NishikawaHSakaguchiS. Regulatory T cells in tumor immunity. Int J Cancer2010; 127(4): 759–767.
112.
FrenchKJSchrecengostRSLeeBD, et al. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res2003; 63(18): 5962–5969.
113.
KapposLBar-OrACreeBAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): A double-blind, randomised, phase 3 study. Lancet2018; 391(10127): 1263–1273.
114.
CreeBASelmajKWSteinmanL, et al. Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial. Mult Scler2022; 28(12): 1944–1962.
115.
O’ConnorPWolinskyJSConfavreuxC, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med2011; 365(14): 1293–1303.
116.
VermerschPCzlonkowskaAGrimaldiLM, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: A randomised, controlled phase 3 trial. Mult Scler2014; 20(6): 705–716.
117.
LandaisAAlhendiRGouverneurA, et al. A case of lymphoma in a patient on teriflunomide treatment for relapsing multiple sclerosis. Mult Scler Relat Disord2017; 17: 92–94.
118.
HuangOZhangWZhiQ, et al. Teriflunomide, an immunomodulatory drug, exerts anticancer activity in triple negative breast cancer cells. Exp Biol Med (Maywood)2015; 240(4): 426–437.
119.
SakyaJThomasKSturgeonA. Regression of basal cell carcinomas in multiple sclerosis patient on aubagio treatment. Southwest Respir Crit Care Chronicles2017; 5: 55.
120.
DietrichSKrämerOHHahnE, et al. Leflunomide induces apoptosis in fludarabine-resistant and clinically refractory CLL cells. Clin Cancer Res2012; 18(2): 417–431.
121.
BaumannPMandl-WeberSVölklA, et al. Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells. Mol Cancer Ther2009; 8(2): 366–375.
122.
CookMRPinchotSNJaskula-SztulR, et al. Identification of a novel Raf-1 pathway activator that inhibits gastrointestinal carcinoid cell growth. Mol Cancer Ther2010; 9(2): 429–437.
123.
HailNJrChenPBushmanLR. Teriflunomide (leflunomide) promotes cytostatic, antioxidant, and apoptotic effects in transformed prostate epithelial cells: Evidence supporting a role for teriflunomide in prostate cancer chemoprevention. Neoplasia2010; 12(6): 464–475.
124.
WhiteRMCechJRatanasirintrawootS, et al. DHODH modulates transcriptional elongation in the neural crest and melanoma. Nature2011; 471(7339): 518–522.
125.
SykesDB. The emergence of dihydroorotate dehydrogenase (DHODH) as a therapeutic target in acute myeloid leukemia. Expert Opin Ther Targets2018; 22(11): 893–898.
126.
GoldRKapposLArnoldDL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med2012; 367(12): 1098–1107.
127.
FoxRJMillerDHPhillipsJT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med2012; 367(12): 1087–1097.
128.
Gómez-MorenoMSánchez-SecoVGMoreno-GarcíaS, et al. Cancer diagnosis in a Spanish cohort of multiple sclerosis patients under dimethylfumarate treatment. Mult Scler Relat Disord2021; 49: 102747.
129.
Gil-BernalRGonzález-CaballeroJLEspinosa-RossoR, et al. Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients. Sci Rep2021; 11(1): 12533.
130.
BoothLCruickshanksNTavallaiS, et al. Regulation of dimethyl-fumarate toxicity by proteasome inhibitors. Cancer Biol Ther2014; 15(12): 1646–1657.
131.
SaiduNENoéGCerlesO, et al. Dimethyl fumarate controls the NRF2/DJ-1 axis in cancer cells: Therapeutic applications. Mol Cancer Ther2017; 16(3): 529–539.
132.
Bennett SaiduNEBretagneMMansuetAL, et al. Dimethyl fumarate is highly cytotoxic in KRAS mutated cancer cells but spares non-tumorigenic cells. Oncotarget2018; 9(10): 9088–9099.
133.
SingerBAArnoldDLDrulovicJ, et al. Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study. Mult Scler2023; 29(14): 1795–1807.
134.
NaismithRTWundesAZiemssenT, et al. Diroximel fumarate demonstrates an improved gastrointestinal tolerability profile compared with dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: Results from the randomized, double-blind, phase III EVOLVE-MS-2 study. CNS Drugs2020; 34(2): 185–196.
135.
GiovannoniGComiGCookS, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med2010; 362(5): 416–426.
136.
GiovannoniGCookSRammohanK, et al. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: A post-hoc and subgroup analysis. Lancet Neurol2011; 10(4): 329–337.
137.
PakpoorJDisantoGAltmannDR, et al. No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine. Neurol Neuroimmunol Neuroinflamm2015; 2(6): e158.
138.
LeistTCookSComiG, et al. Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis. Mult Scler Relat Disord2020; 46: 102572.
139.
LeeMWParkerWBXuB. New insights into the synergism of nucleoside analogs with radiotherapy. Radiat Oncol2013; 8(1): 223.
140.
SantanaVMMirroJJrHarwoodFC, et al. A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia. J Clin Oncol1991; 9(3): 416–422.
141.
SantanaVMMirroJJrKearnsC, et al. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol1992; 10(3): 364–370.
142.
InabaHStewartCFCrewsKR, et al. Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia. Cancer2010; 116(1): 98–105.
143.
StineKCSaylorsRLSaccenteS, et al. Efficacy of continuous infusion 2-CDA (cladribine) in pediatric patients with Langerhans cell histiocytosis. Pediatr Blood Cancer2004; 43(1): 81–84.
144.
InwardsDJFishkinPALaPlantBR, et al. Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma. Ann Oncol2014; 25(10): 2020–2024.
145.
RosenbergJDBurianCWaalenJ, et al. Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: A single-institution series. Blood2014; 123(2): 177–183.
146.
JägerGNeumeisterPBrezinschekR, et al. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: A phase II study. J Clin Oncol2002; 20(18): 3872–3877.
147.
FreyerCWGuptaNWetzlerM, et al. Revisiting the role of cladribine in acute myeloid leukemia: An improvement on past accomplishments or more old news?Am J Hematol2015; 90(1): 62–72.
148.
ColesAJCohenJAFoxEJ, et al. Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings. Neurology2017; 89(11): 1117–1126.
149.
HavrdovaEArnoldDLCohenJA, et al. Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy. Neurology2017; 89(11): 1107–1116.
150.
DemkoSSummersJKeeganP, et al. FDA drug approval summary: Alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia. Oncologist2008; 13(2): 167–174.
151.
HauserSLBar-OrACohenJA, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med2020; 383(6): 546–557.
152.
Bar-OrAGroveRAAustinDJ, et al. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study. Neurology2018; 90(20): e1805–e1814.
153.
van OersMHJKuliczkowskiKSmolejL, et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): An open-label, multicentre, randomised phase 3 study. Lancet Oncol2015; 16(13): 1370–1379.
154.
SalzerJSvenningssonRAlpingP, et al. Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy. Neurology2016; 87(20): 2074–2081.
155.
van VollenhovenRFEmeryPBinghamCOIII, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis2013; 72(9): 1496–1502.
156.
WadströmHFrisellTAsklingJ. Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: A nationwide cohort study from Sweden. JAMA Intern Med2017; 177(11): 1605–1612.
157.
SallesGBarrettMFoàR, et al. Rituximab in B-cell hematologic malignancies: A review of 20 years of clinical experience. Adv Ther2017; 34(10): 2232–2273.
158.
MontalbanXHauserSLKapposL, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med2017; 376(3): 209–220.
159.
HauserSLBar-OrAComiG, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med2017; 376(3): 221–234.
160.
HauserSLKapposLMontalbanX, et al. Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis. Neurology2021; 97(16): e1546–e1559.
161.
MorschhauserFMarltonPVitoloU, et al. Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. Ann Oncol2010; 21(9): 1870–1876.
162.
ZitvogelLApetohLGhiringhelliF, et al. Immunological aspects of cancer chemotherapy. Nat Rev Immunol2008; 8(1): 59–73.
163.
ShurinMRNaiditchHGutkinDW, et al. ChemoImmunoModulation: Immune regulation by the antineoplastic chemotherapeutic agents. Curr Med Chem2012; 19(12): 1792–1803.
164.
VelardiETsaiJJvan den BrinkMRM. T cell regeneration after immunological injury. Nat Rev Immunol2021; 21(5): 277–291.
165.
TurtleCJSwansonHMFujiiN, et al. A distinct subset of self-renewing human memory CD8+ T cells survives cytotoxic chemotherapy. Immunity2009; 31(5): 834–844.
166.
WijayahadiNHaronMRStanslasJ, et al. Changes in cellular immunity during chemotherapy for primary breast cancer with anthracycline regimens. J Chemother2007; 19(6): 716–723.
167.
FagnoniFFLozzaLZiberaC, et al. T-cell dynamics after high-dose chemotherapy in adults: Elucidation of the elusive CD8+ subset reveals multiple homeostatic T-cell compartments with distinct implications for immune competence. Immunology2002; 106(1): 27–37.
168.
MilcentBJosseaumeNPetitprezF, et al. Recovery of central memory and naive peripheral T cells in Follicular Lymphoma patients receiving rituximab-chemotherapy based regimen. Sci Rep2019; 9(1): 13471.
169.
LiuJZhaoJHuL, et al. Low dosages: New chemotherapeutic weapons on the battlefield of immune-related disease. Cell Mol Immunol2011; 8(4): 289–295.
170.
MackallCLFleisherTABrownMR, et al. Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood1997; 89(10): 3700–3707.
171.
BerdDMastrangeloMJ. Effect of low dose cyclophosphamide on the immune system of cancer patients: Depletion of CD4+, 2H4+ suppressor-inducer T-cells. Cancer Res1988; 48(6): 1671–1675.
172.
NorthRJ. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med1982; 155(4): 1063–1074.
173.
LutsiakMESemnaniRTDe PascalisR, et al. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood2005; 105(7): 2862–2868.
174.
GlaserM. Regulation of specific cell-mediated cytotoxic response against SV40-induced tumor associated antigens by depletion of suppressor T cells with cyclophosphamide in mice. J Exp Med1979; 149(3): 774–779.
175.
BroeckerFShaninELysovN, et al. Chemotherapy-induced, broadly reactive autoantibodies in a colon cancer patient. Cureus2022; 14(11): e31954.
176.
SutmullerRPvan DuivenvoordeLMvan ElsasA, et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med2001; 194(6): 823–832.
177.
GhiringhelliFMenardCPuigPE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother2007; 56(5): 641–648.
178.
SchiavoniGMatteiFDi PucchioT, et al. Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: Implications for strategies of chemoimmunotherapy of cancer. Blood2000; 95(6): 2024–2030.
179.
GhiringhelliFMénardCTermeM, et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med2005; 202(8): 1075–1085.
180.
BruniECazzettaVDonadonM, et al. Chemotherapy accelerates immune-senescence and functional impairments of Vδ2pos T cells in elderly patients affected by liver metastatic colorectal cancer. J Immunother Cancer2019; 7(1): 347.
181.
HaflerDAWeinerHL. Immunologic mechanisms and therapy in multiple sclerosis. Immunol Rev1995; 144: 75–107.
182.
WeinerHLCohenJA. Treatment of multiple sclerosis with cyclophosphamide: Critical review of clinical and immunologic effects. Mult Scler2002; 8(2): 142–154.
183.
GonsetteREDemontyLDelmotteP. Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years. J Neurol1977; 214(3): 173–181.
184.
GonsetteRDemontyLDelmotteP (eds). Intensive immunosuppression with cyclophosphamide in remittent forms of multiple sclerosis. A follow-up of 134 patients for 2–10 years. In: BauerHJPoserSRitterG (eds) Progress in multiple sclerosis research. Cham: Springer, 1980, pp. 401–406.
185.
CarterJLHaflerDADawsonDM, et al. Immunosuppression with high-dose i.v. Cyclophosphamide and ACTH in progressive multiple sclerosis: Cumulative 6-year experience in 164 patients. Neurology1988; 38(7, Suppl. 2): 9–14.
186.
WeinerHLMackinGAOravEJ, et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: Final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology1993; 43(5): 910–918.
187.
The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group. Lancet1991; 337(8739): 441–446.
188.
FoxEJ. Management of worsening multiple sclerosis with mitoxantrone: A review. Clin Ther2006; 28(4): 461–474.
189.
ScottLJFiggittDP. Mitoxantrone: A review of its use in multiple sclerosis. CNS Drugs2004; 18(6): 379–396.
190.
MesarosSStojsavljevićNDujmovićI, et al. [Evaluation of the long term effect of mitoxantrone on neurological disability in patients with active multiple sclerosis]. Srp Arh Celok Lek2004; 132(7–8): 209–213.
191.
MariottiniADe MatteisECencioniMT, et al. Haematopoietic stem cell transplantation for the treatment of multiple sclerosis: Recent advances. Curr Neurol Neurosci Rep2023; 23(9): 507–520.
192.
KalincikTSharminSRoosI, et al. Comparative effectiveness of autologous hematopoietic stem cell transplant vs fingolimod, natalizumab, and ocrelizumab in highly active relapsing-remitting multiple sclerosis. JAMA Neurol2023; 80(7): 702–713.
193.
NylanderANSinghJPooleS, et al. Clinical course of multiple sclerosis and patient experiences during breast cancer treatment. Mult Scler2023; 29(8): 967–978.
194.
MillacPMillerH. Cyclophosphamide in multiple sclerosis. Lancet1969; 1(7598): 783.
195.
YalachkovYDabanliDWengerKJ, et al. Concurrent CNS tumors and multiple sclerosis: Retrospective single-center cohort study and lessons for the clinical management. Neurol Sci2022; 43(9): 5513–5522.
KehlKLYangSAwadMM, et al. Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer. Cancer Immunol Immunother2019; 68(6): 917–926.
198.
LeeCDrobniZDZafarA, et al. Pre-existing autoimmune disease increases the risk of cardiovascular and noncardiovascular events after immunotherapy. JACC CardioOncol2022; 4(5): 660–669.
199.
GettingsEJHackettCTScottTF. Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma. Mult Scler2015; 21(5): 670.
200.
CaoYNylanderARamananS, et al. CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment. Neurology2016; 86(16): 1553–1556.
201.
GerdesLAHeldKBeltránE, et al. CTLA4 as immunological checkpoint in the development of multiple sclerosis. Ann Neurol2016; 80(2): 294–300.
202.
YshiiLMHohlfeldRLiblauRS. Inflammatory CNS disease caused by immune checkpoint inhibitors: Status and perspectives. Nat Rev Neurol2017; 13(12): 755–763.
203.
LuBYIsitanCMahajanA, et al. Intracranial complications from immune checkpoint therapy in a patient with NSCLC and multiple sclerosis: Case report. JTO Clin Res Rep2021; 2(6): 100183.
204.
International Multiple Sclerosis Genetics Consortium. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science2019; 365(6460): eaav7188.
205.
Gómez VicenteLRubio ViqueiraBJimenez de las PeñasM, et al. P04.07 Relapse in a paucisymptomatic form of multiple sclerosis in a patient treated with nivolumab. Neuro Oncol2016; 18(Suppl. 4): iv25.
206.
RomeoMALGarassinoMCMoiolaL, et al. Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer. J Neurol2019; 266(12): 3163–3166.
207.
KählerKCEigentlerTKGesierichA, et al. Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders. Cancer Immunol Immunother2018; 67(5): 825–834.
208.
KyiCCarvajalRDWolchokJD, et al. Ipilimumab in patients with melanoma and autoimmune disease. J Immunother Cancer2014; 2(1): 35.
209.
NeuzilKGessnerKHedgepethJ, et al. Complete pathologic response to pembrolizumab and axitinib in a patient with sarcomatoid RCC and ocrelizumab-treated multiple sclerosis. Urology2022; 164: 50–54.
210.
Hasan AliOBernerFAckermannCJ, et al. Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients. Cancer Immunol Immunother2021; 70(2): 563–568.
211.
OliveiraMCBde BritoMHSimabukuroMM. Central nervous system demyelination associated with immune checkpoint inhibitors: Review of the literature. Front Neurol2020; 11: 538695.
212.
QuinnCRajarajanPKopinskyH, et al. Multi-institutional study of neurologic outcomes in people with multiple sclerosis who are treated with immune checkpoint inhibitors for oncologic indications (PL4.004). Neurology2024; 102(17, Suppl. 1): 6774.
213.
Abstracts from the 38th Annual Meeting of the Consortium of Multiple Sclerosis Centers: May 29-June 1, 2024 · Nashville, Tennessee. Int J MS Care2024; 26(S1): 1–104.
214.
ConwaySEPuaDKAHolroydKB, et al. Neurologic disease activity in people with multiple sclerosis treated with immune checkpoint inhibitors. Mult Scler2023; 29(3): 471–474.
215.
AndrodiasGNoroyLPsimarasD, et al. Impact of immune checkpoint inhibitors on the course of multiple sclerosis. Neurol Neuroimmunol Neuroinflamm2024; 11(2): e200202.
216.
AounRGratchDKaminetzkyD, et al. Immune checkpoint inhibitors in patients with pre-existing neurologic autoimmune disorders. Curr Neurol Neurosci Rep2023; 23(11): 735–750.
217.
GarciaCRJayswalRAdamsV, et al. Multiple sclerosis outcomes after cancer immunotherapy. Clin Transl Oncol2019; 21(10): 1336–1342.
218.
DamskyWJilaveanuLTurnerN, et al. B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors. J Immunother Cancer2019; 7(1): 153.
219.
DeftereosSNGeorgonikouD. Effectiveness of rituximab in treating immune-checkpoint-inhibitor-induced immune-related adverse events: Results of a systematic review. Ann Oncol2021; 32(2): 282–283.
220.
BrahmerJRLacchettiCSchneiderBJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol2018; 36(17): 1714–1768.
221.
DoniaMPedersenMSvaneIM. Cancer immunotherapy in patients with preexisting autoimmune disorders. Semin Immunopathol2017; 39(3): 333–337.
222.
LibertCDejagerL. How steroids steer T cells. Cell Rep2014; 7(4): 938–939.
223.
ArbourKCMezquitaLLongN, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol2018; 36(28): 2872–2878.
224.
ChassetFPagesCBiardL, et al. Single-center study under a French Temporary Authorization for Use (TAU) protocol for ipilimumab in metastatic melanoma: Negative impact of baseline corticosteroids. Eur J Dermatol2015; 25(1): 36–44.
225.
MargolinKErnstoffMSHamidO, et al. Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial. Lancet Oncol2012; 13(5): 459–465.
226.
ScottSCPennellNA. Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab. J Thorac Oncol2018; 13(11): 1771–1775.
227.
DowneySGKlapperJASmithFO, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res2007; 13(22, Pt. 1): 6681–6688.
228.
HorvatTZAdelNGDangTO, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol2015; 33(28): 3193–3198.
229.
Vázquez-MonteroLde la GalaMde la Cruz-MerinoL. Nivolumab plus ipilimumab in metastatic melanoma: A critical appraisal focused on specific subpopulations. Front Oncol2023; 13: 1187840.
230.
PetrelliFSignorelliDGhidiniM, et al. Association of steroids use with survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Cancers (Basel)2020; 12(3): 546.
231.
HsuSBoveR. Hormonal therapies in multiple sclerosis: A review of clinical data. Curr Neurol Neurosci Rep2024; 24(1): 1–15.
232.
BurneyBOGarciaJM. Hypogonadism in male cancer patients. J Cachexia Sarcopenia Muscle2012; 3(3): 149–155.
233.
PoniatowskiBCGrimmPCohenG. Chemotherapy-induced menopause: A literature review. Cancer Invest2001; 19(6): 641–648.
234.
BrydøyMFossåSDDahlO, et al. Gonadal dysfunction and fertility problems in cancer survivors. Acta Oncologica2007; 46(4): 480–489.
235.
BehjatiSFrankMH. The effects of tamoxifen on immunity. Curr Med Chem2009; 16(24): 3076–3080.
236.
BelkaCBudachWKortmannRD, et al. Radiation induced CNS toxicity–Molecular and cellular mechanisms. Br J Cancer2001; 85(9): 1233–1239.
237.
MurphyCBHashimotoSAGraebD, et al. Clinical exacerbation of multiple sclerosis following radiotherapy. Arch Neurol2003; 60(2): 273–275.
238.
MilicMReesJH. Acute demyelination following radiotherapy for glioma: A cautionary tale. Pract Neurol2017; 17(1): 35–38.
239.
LampertPTomMIRiderWD. Disseminated demyelination of the brain following Co60 (gamma) radiation. Arch Pathol1959; 68: 322–330.
240.
BéhinADelattreJY. Complications of radiation therapy on the brain and spinal cord. Semin Neurol2004; 24(4): 405–417.
241.
MillerRCLachanceDHLucchinettiCF, et al. Multiple sclerosis, brain radiotherapy, and risk of neurotoxicity: The Mayo Clinic experience. Int J Radiat Oncol Biol Phys2006; 66(4): 1178–1186.
242.
RiccardiFDal BoMMacorP, et al. A comprehensive overview on antibody-drug conjugates: From the conceptualization to cancer therapy. Front Pharmacol2023; 14: 1274088.
243.
Ten BoschGJABolkJ‘t HartBA, et al. Multiple sclerosis is linked to MAPK(ERK) overactivity in microglia. J Mol Med (Berl)2021; 99(8): 1033–1042.
244.
KotelnikovaEKianiNAMessinisD, et al. MAPK pathway and B cells overactivation in multiple sclerosis revealed by phosphoproteomics and genomic analysis. Proc Natl Acad Sci U S A2019; 116(19): 9671–9676.
245.
KrämerJBar-OrATurnerTJ, et al. Bruton tyrosine kinase inhibitors for multiple sclerosis. Nat Rev Neurol2023; 19(5): 289–304.
246.
BallJArcherSWardS. PI3K inhibitors as potential therapeutics for autoimmune disease. Drug Discov Today2014; 19(8): 1195–1199.
247.
RiveraADAzimKMacchiV, et al. Epidermal growth factor pathway in the age-related decline of oligodendrocyte regeneration. Front Cell Neurosci2022; 16: 838007.
248.
TavassolyOSatoTTavassolyI. Inhibition of brain epidermal growth factor receptor activation: A novel target in neurodegenerative diseases and brain injuries. Mol Pharmacol2020; 98(1): 13–22.
249.
PapeKProtopapaMSchraadM, et al. Case report: Balancing immune responses – Multiple sclerosis disease exacerbation under BRAF/MEK treatment for malignant melanoma. Front Oncol2023; 13: 1303141.
250.
HemondCCBakshiRTauhidS, et al. Exacerbation of multiple sclerosis by BRAF/MEK treatment for malignant melanoma: The central vein sign to distinguish demyelinating lesions from metastases. J Investig Med High Impact Case Rep2021; 9: 23247096211033047.
251.
LinW. Neuroprotective effects of vascular endothelial growth factor A in the experimental autoimmune encephalomyelitis model of multiple sclerosis. Neural Regen Res2017; 12(1): 70–71.
252.
GentileMTMutoGLusG, et al. Angiogenesis and multiple sclerosis pathogenesis: A glance at new pharmaceutical approaches. J Clin Med2022; 11(16): 4643.
253.
ProescholdtMAJacobsonSTresserN, et al. Vascular endothelial growth factor is expressed in multiple sclerosis plaques and can induce inflammatory lesions in experimental allergic encephalomyelitis rats. J Neuropathol Exp Neurol2002; 61(10): 914–925.
254.
MeiraMSieversCHoffmannF, et al. PARP-1 deregulation in multiple sclerosis. Mult Scler J Exp Transl Clin2019; 5(4): 2055217319894604.
255.
WangYPleasureDDengW, et al. Therapeutic potentials of poly (ADP-Ribose) polymerase 1 (PARP1) inhibition in multiple sclerosis and animal models: Concept revisiting. Adv Sci2022; 9(5): 2102853.
256.
MekhaeilMDevKKConroyMJ. Existing evidence for the repurposing of PARP-1 inhibitors in rare demyelinating diseases. Cancers2022; 14(3): 687.
257.
CavoneLChiarugiA. Targeting poly (ADP-ribose) polymerase-1 as a promising approach for immunomodulation in multiple sclerosis?Trends Mol Med2012; 18(2): 92–100.
